' () acquisition of Price Bailey was too good an opportunity to turn down Brian Raven, chief executive, told Proactive Investors.
Talks had been underway for two years before the deal was struck he added.
Price Bailey brings with it a chunk of high net worth clients, a profitable advisory business and the chance to build a significant private client operation with an award winning business.
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event,
London , 24 January 2019.
Register here »